Publications
182 results found
Nemzoff C, Ahmed N, Olufiranye T, et al., 2024, Rapid cost-effectiveness analysis: hemodialysis versus peritoneal dialysis for patients with acute kidney injury in Rwanda., Cost Eff Resour Alloc, Vol: 22, ISSN: 1478-7547
BACKGROUND: To ensure the long-term sustainability of its Community-Based Health Insurance scheme, the Government of Rwanda is working on using Health Technology Assessment (HTA) to prioritize its resources for health. The objectives of the study were to rapidly assess (1) the cost-effectiveness and (2) the budget impact of providing PD versus HD for patients with acute kidney injury (AKI) in the tertiary care setting in Rwanda. METHODS: A rapid cost-effectiveness analysis for patients with AKI was conducted to support prioritization. An 'adaptive' HTA approach was undertaken by adjusting the international Decision Support Initiative reference case for time and data constraints. Available local and international data were used to analyze the cost-effectiveness and budget impact of peritoneal dialysis (PD) compared with hemodialysis (HD) in the tertiary hospital setting. RESULTS: The analysis found that HD was slightly more effective and slightly more expensive in the payer perspective for most patients with AKI (aged 15-49). HD appeared to be cost-effective when only comparing these two dialysis strategies with an incremental cost-effectiveness ratio of 378,174 Rwandan francs (RWF) or 367 United States dollars (US$), at a threshold of 0.5 × gross domestic product per capita (RWF 444,074 or US$431). Sensitivity analysis found that reducing the cost of HD kits would make HD even more cost-effective. Uncertainty regarding PD costs remains. Budget impact analysis demonstrated that reducing the cost of the biggest cost driver, HD kits, could produce significantly more savings in five years than switching to PD. Thus, price negotiations could significantly improve the efficiency of HD provision. CONCLUSION: Dialysis is costly and covered by insurance in many countries for the financial protection of patients. This analysis enabled policymakers to make evidence-based decisions to improve the efficiency of dialysis provision.
Whitty JA, Littlejohns P, Ratcliffe J, et al., 2023, Impact of information and deliberation on the consistency of preferences for prioritization in health care - evidence from discrete choice experiments undertaken alongside citizens' juries, JOURNAL OF MEDICAL ECONOMICS, Vol: 26, Pages: 1237-1249, ISSN: 1369-6998
Baltussen R, Surgey G, Vassall A, et al., 2023, The use of cost-effectiveness analysis for health benefit package design - should countries follow a sectoral, incremental or hybrid approach?, COST EFFECTIVENESS AND RESOURCE ALLOCATION, Vol: 21, ISSN: 1478-7547
Angelis A, Harker M, Cairns J, et al., 2023, The Evolving Nature of Health Technology Assessment: A Critical Appraisal of NICE's New Methods Manual, VALUE IN HEALTH, Vol: 26, Pages: 1503-1509, ISSN: 1098-3015
Charlton V, Distefano M, Mitchell P, et al., 2023, We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment, HEALTH ECONOMICS POLICY AND LAW, ISSN: 1744-1331
Lay PRD, Benzaken A, Karim QA, et al., 2023, Ending AIDS as a public health threat by 2030: Time to reset targets for 2025, Advances in Surgical and Medical Specialties, Pages: 777-783, ISBN: 9789814877459
Quaife M, Medley GF, Jit M, et al., 2022, Considering equity in priority setting using transmission models: Recommendations and data needs, Epidemics: the journal of infectious disease dynamics, Vol: 41, Pages: 1-8, ISSN: 1755-4365
ObjectivesDisease transmission models are used in impact assessment and economic evaluations of infectious disease prevention and treatment strategies, prominently so in the COVID-19 response. These models rarely consider dimensions of equity relating to the differential health burden between individuals and groups. We describe concepts and approaches which are useful when considering equity in the priority setting process, and outline the technical choices concerning model structure, outputs, and data requirements needed to use transmission models in analyses of health equity.MethodsWe reviewed the literature on equity concepts and approaches to their application in economic evaluation and undertook a technical consultation on how equity can be incorporated in priority setting for infectious disease control. The technical consultation brought together health economists with an interest in equity-informative economic evaluation, ethicists specialising in public health, mathematical modellers from various disease backgrounds, and representatives of global health funding and technical assistance organisations, to formulate key areas of consensus and recommendations.ResultsWe provide a series of recommendations for applying the Reference Case for Economic Evaluation in Global Health to infectious disease interventions, comprising guidance on 1) the specification of equity concepts; 2) choice of evaluation framework; 3) model structure; and 4) data needs. We present available conceptual and analytical choices, for example how correlation between different equity- and disease-relevant strata should be considered dependent on available data, and outline how assumptions and data limitations can be reported transparently by noting key factors for consideration.ConclusionsCurrent developments in economic evaluations in global health provide a wide range of methodologies to incorporate equity into economic evaluations. Those employing infectious disease models need to use the
Soril LJJ, Elshaug AG, Esmail R, et al., 2022, Developing a How-to-Guide for Health Technology Reassessment: "The HTR Playbook", INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, Vol: 11, Pages: 2525-2532
Sampson C, Zamora B, Watson S, et al., 2022, Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy, APPLIED HEALTH ECONOMICS AND HEALTH POLICY, Vol: 20, Pages: 651-667, ISSN: 1175-5652
- Author Web Link
- Cite
- Citations: 6
Barlow E, Morton A, Dabak S, et al., 2022, What is the value of explicit priority setting for health interventions? A simulation study, HEALTH CARE MANAGEMENT SCIENCE, Vol: 25, Pages: 460-483, ISSN: 1386-9620
McBain R, Nandakumar AK, Ruffner M, et al., 2022, A new initiative to track HIV resource allocation and costs, BULLETIN OF THE WORLD HEALTH ORGANIZATION, Vol: 100, Pages: 358-359, ISSN: 0042-9686
Krubiner CB, Barsdorf NW, Goldstein SJ, et al., 2022, Developing and piloting a context-specified ethics framework for health technology assessment: the South African Values and Ethics for Universal Health Coverage approach, INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, Vol: 38, ISSN: 0266-4623
- Author Web Link
- Cite
- Citations: 3
Teerawattananon Y, Sarin KC, Chi Y-L, et al., 2022, Recalibrating the notion of modelling for policymaking during pandemics, EPIDEMICS, Vol: 38, ISSN: 1755-4365
- Author Web Link
- Cite
- Citations: 6
Kazibwe J, Gheorghe A, Wilson D, et al., 2022, The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review, VALUE IN HEALTH, Vol: 25, Pages: 385-389, ISSN: 1098-3015
- Author Web Link
- Cite
- Citations: 25
Blaauw D, Chambers C, Chirwa T, et al., 2022, Introducing an Ethics Framework for health priority-setting in South Africa on the path to universal health coverage, SAMJ SOUTH AFRICAN MEDICAL JOURNAL, Vol: 112, Pages: 240-244, ISSN: 0256-9574
- Author Web Link
- Cite
- Citations: 3
Colson AR, Morton A, Ardal C, et al., 2021, Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?, VALUE IN HEALTH, Vol: 24, Pages: 1828-1834, ISSN: 1098-3015
- Author Web Link
- Cite
- Citations: 9
Culyer AJ, Chalkidou K, 2021, Organising Research and Development for evidence-informed health care: some universal characteristics and a case study from the UK, HEALTH ECONOMICS POLICY AND LAW, Vol: 16, Pages: 489-504, ISSN: 1744-1331
Teerawattananon Y, Painter C, Dabak S, et al., 2021, Avoiding health technology assessment: a global survey of reasons for not using health technology assessment in decision making, COST EFFECTIVENESS AND RESOURCE ALLOCATION, Vol: 19, ISSN: 1478-7547
- Author Web Link
- Cite
- Citations: 10
Turner H, Archer R, Downey L, et al., 2021, An introduction to the main types of economic evaluations used for informing priority setting and resource allocation in healthcare: key features, uses and limitations, Frontiers in Public Health, Vol: 9, Pages: 1-17, ISSN: 2296-2565
Economic evidence is increasingly being used for informing health policies. However, the underlining principles of health economic analyses are not always fully understood by non-health economists, and inappropriate types of analyses, as well as inconsistent methodologies, may be being used for informing health policy decisions. In addition, there is a lack of open access information and methodological guidance targeted to public health professionals particularly those based in low- and middle-income country (LMIC) settings. The objective of this review is to provide a comprehensive and accessible introduction to economic evaluations for public health professionals with a focus on LMIC settings. We cover the main principles underlining the most common types of full economic evaluations used in healthcare decision making in the context of priority setting (namely cost-effectiveness/cost-utility analyses, cost-benefit analyses), and outline their key features, strengths and weaknesses. It is envisioned that this will help those conducting such analyses, as well as stakeholders that need to interpret their output, gain a greater understanding of these methods and help them select/distinguish between the different approaches. In particular, we highlight the need for greater awareness of the methods used to place a monetary value on the health benefits of interventions, and the potential for such estimates to be misinterpreted. Specifically, the economic benefits reported are typically an approximation, summarizing the health benefits experienced by a population monetarily in terms of individual preferences or potential productivity gains, rather than actual realisable or fiscal monetary benefits to payers or society.
Cyr PR, Jain V, Chalkidou K, et al., 2021, Evaluations of public health interventions produced by health technology assessment agencies: A mapping review and analysis by type and evidence content, HEALTH POLICY, Vol: 125, Pages: 1054-1064, ISSN: 0168-8510
- Author Web Link
- Cite
- Citations: 3
Hollingworth S, Fenny AP, Yu S-Y, et al., 2021, Health technology assessment in sub-Saharan Africa: a descriptive analysis and narrative synthesis, COST EFFECTIVENESS AND RESOURCE ALLOCATION, Vol: 19, ISSN: 1478-7547
- Author Web Link
- Cite
- Citations: 12
Millar R, Morton A, Bufali MV, et al., 2021, Assessing the performance of health technology assessment (HTA) agencies: developing a multi-country, multi-stakeholder, and multi-dimensional framework to explore mechanisms of impact, COST EFFECTIVENESS AND RESOURCE ALLOCATION, Vol: 19, ISSN: 1478-7547
- Author Web Link
- Cite
- Citations: 2
Gheorghe A, Maringe C, Spice J, et al., 2021, Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: A national population-based modelling study in England, UK, EUROPEAN JOURNAL OF CANCER, Vol: 152, Pages: 233-242, ISSN: 0959-8049
- Author Web Link
- Cite
- Citations: 27
De Lay PR, Benzaken A, Karim QA, et al., 2021, Ending AIDS as a public health threat by 2030: Time to reset targets for 2025, PLOS MEDICINE, Vol: 18, ISSN: 1549-1277
- Author Web Link
- Cite
- Citations: 14
Towse A, Chalkidou K, Firth I, et al., 2021, How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?, VALUE IN HEALTH, Vol: 24, Pages: 625-631, ISSN: 1098-3015
- Author Web Link
- Cite
- Citations: 8
Nemzoff C, Ruiz F, Chalkidou K, et al., 2021, Adaptive health technology assessment to facilitate priority setting in low- and middle-income countries, BMJ GLOBAL HEALTH, Vol: 6, ISSN: 2059-7908
- Author Web Link
- Cite
- Citations: 13
Gopinathan U, Ottersen T, Cyr P-R, et al., 2021, Evidence-Informed Deliberative Processes for HTA Around the Globe: Exploring the Next Frontiers of HTA and Best Practices Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe", INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, Vol: 10, Pages: 232-236
- Author Web Link
- Cite
- Citations: 2
Cookson R, Griffin S, Norheim OF, et al., 2021, Distributional Cost-Effectiveness Analysis Comes of Age, VALUE IN HEALTH, Vol: 24, Pages: 118-120, ISSN: 1098-3015
- Author Web Link
- Cite
- Citations: 37
Regan L, Wilson D, Chalkidou K, et al., 2021, The journey to UHC: how well are vertical programmes integrated in the health benefits package? A scoping review, BMJ GLOBAL HEALTH, Vol: 6, ISSN: 2059-7908
- Author Web Link
- Cite
- Citations: 3
Dawoud D, Chalkidou K, Sullivan R, et al., 2020, USA stockpiling of remdesivir: How should the world respond?, JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, Vol: 9, Pages: 1243-1246, ISSN: 2042-6305
- Author Web Link
- Cite
- Citations: 2
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.